ARMEN GARO H 4
4 · AGENUS INC · Filed Feb 9, 2026
Research Summary
AI-generated summary of this filing
Agenus CEO Garo Armen Receives Award of 5,027 Shares
What Happened Garo H. Armen, Chairman, Chief Executive Officer and Principal Financial Officer of Agenus Inc. (AGEN), received 5,027 shares of common stock on February 6, 2026 as compensation (salary paid in stock). The shares were recorded at a closing price of $2.94, giving the issuance a reported value of $14,779. The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.
Key Details
- Transaction type: Award/Grant (salary paid in stock) on 2026-02-06
- Shares received: 5,027 at $2.94 per share; total reported value $14,779
- Filing date / timeliness: Form 4 filed 2026-02-09; no late filing indicated
- Vesting/tax: Shares are fully vested on issuance (per plan); no separate tax-withholding code reported
- Holding: Reported shares are held in Dr. Armen's IRA accounts
- Other holdings disclosed: Dr. Armen is trustee and has investment authority for a GRAT holding 23,950 shares and is a general partner in Pixie Partners (owns 5,000 shares); he disclaims beneficial ownership to the extent of pecuniary interest in Pixie
Context This transaction reflects salary compensation converted into equity rather than a market purchase or sale. Such issuances are common for executives electing stock payment and do not, by themselves, indicate a buy or sell signal; they increase insider stock ownership in-kind but are not open-market purchases.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-02-06$2.94/sh+5,027$14,779→ 320,712 total
- 31,298(indirect: See Footnote)
Common Stock
[F3] - 28,950(indirect: See Footnote)
Common Stock
[F4]
Footnotes (4)
- [F1]At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 6, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
- [F2]$2.94 is the closing price of our Common Stock on February 6, 2026, the last trading day for the payroll date for the pay period ending February 6, 2026.
- [F3]Shares are held in Dr. Armen's IRA accounts.
- [F4]Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.